Van Andel Research Institute (VARI) researchers have determined how two proteins mandatory for the initiation and development of prostate cancer interact at the molecular level, which could lead to improved therapys for the disease. One of the proteins, androgen receptor, is already an important drug target for prostate cancer. The other, steroid receptor coactivator-3 (SRC3), was originally identified for its role in the development of breast cancer. SCR3 has also been characterized as a key factor in the development of prostate cancer, but, until now, the exact relationship between androgen receptor and SCR3 has been unclear........